Rhythm Pharmaceuticals (RYTM) Tops Q2 EPS by 7c

Rhythm Pharmaceuticals (NASDAQ: RYTM) reported Q2 EPS of ($0.89), $0.07 better than the analyst estimate of ($0.96). Revenue for the quarter came in at $9.07 million versus the consensus estimate of $2.57 million.

For earnings history and earnings-related data on Rhythm Pharmaceuticals (RYTM) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Credo Technology pops 3.5% as Evercore initiates with monster $325 price target
• Best Smidcap Ideas: TD Cowen Reiterates Buy Rating on Rhythm Pharmaceuticals (RYTM)